IDH1 and astrocytoma (excluding glioblastoma): Furthermore, the biologic basis of the discrepancy in clinical outcomes with the mismatch repair deficiency conferring worse survival in primary IDH-mutant astrocytomas versus more favorable survival in primary IDH-wildtype glioblastomas compared to their respective non-hypermutant counterparts remains uncertain.